Skip to content
Screener

Sutro Biopharma STRO Total Operating Expenses

Total Operating Expenses at other companies

Xencor logo
XencorXNCR
$88.29M+15.0%
Schrodinger logo
SchrodingerSDGR
$73.98M-6.4%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$60.19M+8.8%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$59.65M+26.0%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$48.77M+1.8%
Arrowhead Research logo
Arrowhead ResearchARWR
$215M+33.1%

Other financials

Income statement

See full
Revenue$9.8M-84.6%
Operating income-$29.9M-794%
Net income-$38.5M-235%
EPS (diluted)-$2.33-72.6%

Balance sheet

See full
Cash & equivalents$54.3M-15.1%
Total debt$10.8M-45.0%
Total equity-$103.3M-222%
Total assets$194.5M-25.9%

Cash flow

See full
Operating cash flow-$38.3M+14.4%
CapEx$256.0K
Free cash flow-$38.5M+13.8%

Valuation

See full
Market cap$423.04M+546%
Enterprise value$379.49M+1,702%
P/S9.3×+8.6×

Profitability

See full
Operating margin-319.6%+540pp
Net margin-395.2%+18,070pp
FCF margin-318.2%+159pp

Returns & leverage

See full
Return on equity-234.2%
Debt / equity0.5×+0.3×
Current ratio3.3×+0.2×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Sutro Biopharma’s 10-Q, filed August 12, 2026.

Filed
Aug 12, 2026, 7:30 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-345748
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Research and development31,69538,32568,24889,922
General and administrative7,83110,34315,41523,616
Restructuring and related costs20118,42224339,465
Total operating expenses39,72767,09083,906153,003
Loss from operations(29,888)(3,345)(59,544)(71,859)
Interest income1,7232,5193,3585,708
Non-cash interest expense related to the sale of future royalties(9,862)(9,647)(19,329)(18,991)
Interest and other income (expense), net(505)(1,044)(1,516)(2,336)

Item 1. Financial Statements.

FAQ

What is Sutro Biopharma's total operating expenses?
Sutro Biopharma (STRO) reported total operating expenses of $39.73M in Q2 2026.
How has Sutro Biopharma's total operating expenses changed year-over-year?
Sutro Biopharma's total operating expenses decreased by 40.8% year-over-year, from $67.09M to $39.73M.
What is the long-term trend for Sutro Biopharma's total operating expenses?
Over 4 years (2021 to 2025), Sutro Biopharma's total operating expenses has grown at a 12.9% compound annual growth rate (CAGR), from $160.4M to $260.85M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.

Ask your AI about Sutro Biopharma's total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude